Computerized System Audits In A GCP Pharmaceutical Laboratory Environment

Size: px
Start display at page:

Download "Computerized System Audits In A GCP Pharmaceutical Laboratory Environment"

Transcription

1 IVTGXP_july06.qxd 6/28/06 1:09 PM Page 36 Computerized System Audits In A GCP Pharmaceutical Laboratory Environment By Maintaining data integrity for both clinical laboratory processes and patient data is pivotal to Good Clinical Practice. Successful system audits are crucial to continuing GCP. Computers and computerized systems are an integral part of daily life in the laboratory. Examples include: laboratory equipment, Laboratory Management Information System (LIMS), the network, servers, databases, and individual workstations, all providing remote access to important data. Government rules, regulations and guidance documents contain specific requirements for computerized systems. One of those regulations is Good Clinical Practice (GCP). As quoted from the International Conference on Harmonization (ICH) Guideline for Good Clinical Practice: GCP is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety, and well-being of trial subjects are protected consistent with the principles that have their origin in the Declaration of Helsinki, and that the clinical trial data are credible. 1 The key point to remember is that clinical laboratories process and manage patient data, and this data is used to make critical medical decisions. If the data a laboratory produces is incorrect, decisions taken may be incorrect, and this could mean: Patients may be harmed Submissions may be delayed or turned down Inaccurate information may be included on the product label Therefore, we must maintain a high confidence level in the integrity of the data to protect patient safety - both during the clinical trials and post-marketing. Scope This article provides a practical and non-technical overview of the most important topics that are typically covered during a computer system laboratory audit. Although the comments and self- 36 Journal of GXP Compliance

2 IVTGXP_july06.qxd 6/28/06 1:09 PM Page 37 audit questions are based on experience in the clinical arena and the regulations (Good Clinical Practice) that govern them, they are equally applicable to other laboratories. Before discussing the audit approach, it is important to define the audit scope. The Food and Drug Administration (FDA) defines a computerized system to Include hardware, software, peripheral devices (equipment that is directly connected (to) a computer), personnel, and documentation; e.g., manuals and Standard Operating Procedures. 2 So, it is not only about hardware and software, the scope is much broader. Defining Audit The International Organization for Standardization (ISO) in document defines an audit as a systematic, independent, and documented process for obtaining audit evidence and evaluating it objectively to determine the extent to which audit criteria are fulfilled. In most instances, the audit evidence will be documentation (electronic or paper) that proves that requirements have been met. The laboratory staff, Information Technology (IT), and the Quality Control/Quality Assurance Departments must work together to understand how IT impacts their business and how to set appropriate controls that comply with regulatory and client requirements. Client auditors or regulatory body representatives perform audits on the facilities and processes. As part of these audits, it is highly likely that the laboratory will be inspected. Audit Standard All audits are conducted against a standard. In the case of computerized systems, there are multiple documents that create the standards that are used during the audit. A critical standard is the U.S. FDA s Code of Federal Regulations (CFR) 21 Part In August 1997, the FDA effected 21 CFR Part 11 on Electronic Records; Electronic Signatures. The FDA issued this regulation to provide criteria for acceptance of electronic records and electronic signatures. The original intention was to permit the widest use of electronic technology compatible with FDA's responsibility to promote and protect public health. However, there are still discussions going on around the interpretation and scope of Part 11. A number of guidance documents were issued and withdrawn again as described in the current guidance for industry on Part 11, Electronic Records; Electronic Signatures - Scope and Application. 5 An FDA guidance contains nonbinding recommendations and represents FDA s current thinking on a subject. Since the scope of Part 11 was interpreted very broadly by Industry, the FDA tried to narrow the scope and elucidate more about the scope in the 2004 Draft Guidance for Industry on Computerized Systems Used in Clinical Trials 6 (hereinafter referred to as 2004 Draft Guidance ): This document provides guidance about computerized systems that are used to create, modify, maintain, archive, retrieve, or transmit clinical data required to be maintained and/or submitted to the FDA. These data form the basis for the Agency s decisions regarding the safety and efficacy of new human and animal drugs, biologic products, medical devices, and certain food and color additives. Because the data have broad public health significance, they are expected to be of the highest quality and integrity. This guidance document addresses long-standing FDA regulations concerning clinical trial records. It also addresses requirements of the Electronic Records/Electronic Signature rule (21 CFR Part 11). There are additional predicate rules and regulations in place that impact compliance in a laboratory setting. Predicate rules are requirements set forth in the Act, the PHS Act, 7 or any FDA regulation, with the exception of Part 11. July 2006 Volume 10, Number 4 37

3 IVTGXP_july06.qxd 6/28/06 1:09 PM Page 38 Timing and Agenda Typically an audit starts with analyzing the nature and amount of work done by the auditee. This information can be given by the laboratory or preferably by the person who is managing the laboratory (contract). Often they can provide you valuable information of the laboratory (quality of work provided, data requirements, (problem) area s for investigation, etc.). Furthermore, previous audit reports should be reviewed and other sources could be consulted (e.g.: the website of the auditee often contains valuable information). Applicable rules, regulations, and good business practices should be taken into account as well when setting the scope and objectives of the audit. This might result in an audit lasting one day or up to more than one week. Resulting from this analysis, the scope and objectives of the audit are determined and typically an agenda will be sent to the auditee listing what will be reviewed during the audit. This gives the auditee the opportunity to prepare and have the appropriate staff, documentation, and facilities available. The agenda for a computerized system audit can look like this: General topics and activities: Opening meeting, audit agenda, scope, and objectives Company organization, departmental overview, and reporting structures Tour of facilities and security (including server room) Review of: Company s quality system Documentation practices Personnel records (CV, job descriptions, qualifications, and training) IT standard operating procedures (SOPs), including: - SOP management and training - Software Development Life Cycle (SDLC) and/or software validation - Change control and configuration management - Data back-up, recovery, and archiving - Logical and physical security Copies of the company s business continuity and disaster recovery plans Evidence of the company s compliance with 21 CFR Part 11 (Electronic Record; Electronic Signatures) Closing meeting and discussion of findings Let us now review these agenda items in more detail. Opening Meeting The opening meeting should allow the auditee and the auditors to introduce themselves and to express expectations from and to each other. It is recommended to discuss the agenda and make sure the appropriate staff is available at a convenient time for the auditor. Although it is fairly obvious that the audit will consume a significant amount of the auditee s time, they should, nonetheless, be allowed to run their business, so the auditor must be flexible. After the opening meeting, there should be a mutually clear understanding of the agenda and the expectations. It is recommended to have a daily wrap-up meeting allowing the auditee and the auditor to discuss the progress of the audit and any outstanding questions and issues. Quality System When the actual audit begins, a good starting point is the review of the quality system. A good quality system contains a clear description of expectations. However, quality must also be lived through the company s quality culture. A good way to assess the quality culture is by watching employees do their jobs, and asking questions about how they do them (how do they access SOPs, are they trained on the use of equipment, etc.). A tour around the laboratory facilities is usually included in an audit. Documentation should be organized and contain up-to-date information. Document-naming convention (Quality Manual or Guidance, Procedures, Policies or work instructions) can assist in determining the ease of use of the quality system, so a consistent use of the naming convention throughout the company is important. SOPs should clearly define who is responsible for what. A clear definition of process flow, tasks, responsibilities, and deliverables (e.g., documentation) should be included. This saying is still true: 38 Journal of GXP Compliance

4 IVTGXP_july06.qxd 6/28/06 1:09 PM Page 39 Figure 1 Typical Audit Cycle Plan next Audit (If appropriate) Follow-up on Findings Preparation Send Agenda Review of: Rules and Regulations Guidelines and Good Business Practices Contract and Agreements Previous Audits Involved Risk Communication Audit Report Opening Meeting Audit Close-Out Meeting Review of: Quality System Training Software Validation Business Continuity Plan and Disaster Recovery Plan Data Back-up, Recover and Archiving Logical and Physical Security Compliance with 21 CFR Part 11 If you do it, document it If it is not documented, it is not done Basically, the message is simple: PROPOSED PART 11 APPROACH training if needed? Document your good business practices and take credit for what you do! Does the period between the document (SOP) approval date and the effective date allow sufficient time for reading and employee Do SOPs and other controlled documentation have sufficient version control and document identifiers? In the 2004 Draft Guidance it is recommended Does the company allow simple but secure Determine Predicate Rule Requirements that pertinent SOPs to the use of the computerized system be available on site including: accessibility (paper or electronic)? Is it clearly identified who is supposed to read which documents (e.g.: in a curriculum)? System setup and installation Data collection Narrow and Scope handling - Identify Electronic Records that Require Part 11 Training Compliance Data backup, recovery, and contingency plans Security Training on SOPs (a read and acknowledge form Change control is the minimum) should be documented. In the 2004 System maintenance Draft Guidance, it is furthermore stated: Alternative recording Part 11 methods Records Not Part 11 Records (in case of system unavailability). (This item was added in the 2004 Draft Guidance.) The agency recommends that training be provided to individuals in the specific operations with regard to computerized Assess Risk - Evaluate Level of The challenge is to keep the SOP instructions systems that they are to perform. We Controls Appropriate to Risk always as clear, precise, and flexible as possible. recommend that training be conducted Apart from the content of SOPs, there should also be sufficient guidance regarding management, accessibility, Implement and training Appropriate in the SOPs. Part 11 Some questions to ask Controls regarding document control include the following: by qualified individuals on a continuing basis, as needed, to ensure familiarity with the computerized system and with any changes to the system during the course of the study. July 2006 Volume 10, Number 4 39

5 IVTGXP_july06.qxd 6/28/06 1:09 PM Page 40 In addition, a job-description and Curriculum Vitae (CV) for employees should be available and evidence related to the requirements as specified in the job-description to show that an employee is qualified to do the job as specified. This would satisfy curent regulatory agency expectations.the number of training-related regulatory agency observations has increased significantly during recent years. Software Validation One of the typical tasks IT employees and laboratory personnel are involved in is validation or qualification of computerized systems. A definition of software validation is given by the FDA: Software validation means confirmation by examination and provision of objective evidence that software specifications conform to user needs and intended uses, and that the particular requirements implemented through software can be consistently fulfilled. 6 The level of software validation varies significantly and depends on a number of variables, such as: Type of computerized system - Commercial Off The Shelf (COTS) or in-house or customdeveloped Regulatory and business requirements associated with the intended use of the computerized system Complexity of the computerized system Results of vendor evaluation, if applicable If a company uses only COTS user-configurable (directly out of the box) software, then most likely they only need to verify that the software is installed according to a pre-defined process and that the configuration of any parameters make the software fit for its intended purpose. This is typically documented in an Installation Qualification (IQ) or an Equipment Qualification (EQ). This is intended to: Furthermore, documented verification should occur to demonstrate that, when installed in its production environment, software performs as anticipated and specified in the requirements. The thoroughness of qualification and verification depends on a number of variables, such as the criticality of the system and the risks (i.e., regulatory risks or patient safety) involved. If a company develops software in-house, the SDLC (Software Development Lifecycle) should be described. In-house built data analysis tools, databases, and even spreadsheets should be covered by the SDLC as well. The development of software is a shared effort between IT and the intended user. All anticipated functionalities and user and regulatory requirements must be documented in a clear, consistent, and testable way. A traceability matrix can be used to track these requirements through the design and the testing and should assure that all requirements have been met. When using computerized systems, a company must maintain procedures around change control and configuration management. The change control procedure should cover and describe items such as: Reviewing (software and hardware) changes to assess the impact on software, data, and safety Reviewing and approving proposed changes by appropriate staff Acting upon emergency changes (such as patches or bug fixes) Documenting the change control process Configuration management is linked to change management and is used to record versions of hardware and software at points in time. Version control and release control are important aspects of configuration management to allow traceability of which (software and hardware) versions are installed and when and how software and hardware were and are to be released. Provide control over the installation process Verify proper installation Maintain a record of the installation Establish a starting point for change control 40 Journal of GXP Compliance

6 IVTGXP_july06.qxd 6/28/06 1:09 PM Page 41 Business Continuity Plan and Disaster Recovery Plan Although Business Continuity Planning (BCP) and Disaster Recovery Planning (DRP) are not extensively covered by pharmaceutical regulations, it is a good business practice to have a BCP and DRP. Some questions to ask regarding business continuity and disaster recovery planning: If a disaster were to happen: Can the company still receive, register, and analyze samples when the facilities are no longer available? How would analysis of samples with limited stability continue (blood samples are a good example)? How would capturing data for ongoing analysis continue? Is it necessary to consider alternative sites within hours or days of prosaective or actual downtime? Would extended downtime threaten patient safety? The occurrence of a disaster (e.g., fire) may take a significant number of companies out of business due to the lack of BCP and DRP. In most instances, the compilation of a BCP and DRP is the collective effort between the IT Department and their internal business partners, but should extend beyond computerized systems. The BCP should protect essential business operations in the event that required (computer) systems are not available, by documenting the process that the business will follow until the (computer) systems are restored. A recommendation specifically mentioned in the 2004 Draft Guidance is that a company should have an SOP covering the Alternative Recording Methods (in case of system unavailability). That means that a company should think about how to proceed when one or more computerized systems (e.g., LIMS) are not available. The BCP can encompass a couple of pages for a small company to hundreds of pages for a larger company, or several separated BCPs. Items to think about while developing a BCP include: If the power supply fails, is there a power supply backup (batteries and generator)? Do fire protection and detection systems exist? If so, has the power supply backup and fire protection systems been tested and documented? Has an impact analysis study been performed to identify and quantify the impact of the potential loss of critical business assets? What is the impact if the laboratory is not available for some time? What would it mean to lose one of your key staff members? Is there a crisis plan that specifies the continuation of critical business functions from the time the computerized systems (or building) are unavailable to the time they are returned (or re-built) to production? What would be the impact of the LIMS not being available for some time? Does the plan include processes affected, resources required, and automated operating procedures (e.g., fax, , and telephone) to be used during an outage? Can fax, telephone services, and be easily rerouted to alternate locations? Is there a process in place to capture data outside your LIMS and a validated way to enter it into the system once back to production? Is there a process to integrate the data created or changed outside of the computerized system into the system once it has returned to production? Is there a schedule to test the plan? For example, will the management team meet together annually for one day and simulate the occurrence of a disaster? The DRP has a different objective. The DRP documents the steps to be taken in the event of a disaster to restore the availability of a computerized system. Items to think about while developing a DRP include: Where will the DRP be stored (off-site, fire-proof safe, etc.)? Do key staff have access to the plan(s)? Is a reference needed to other DRPs? Is there a list containing the key internal and external (sponsor) contacts? Is the list up-todate and accurate? July 2006 Volume 10, Number 4 41

7 IVTGXP_july06.qxd 6/28/06 1:09 PM Page 42 Is there an inventory of all systems, equipment, and other resources needed to maintain services (computers, fax, connections, software, etc.)? Can you rebuild the current systems using this information? Is a recovery process and related activities described? What is the verification process to ensure all system components are back in place? Is there a schedule to test the plan? Data Back-up, Recovery, and Archiving Although the backup and recovery procedures are sometimes included in the DRP, it is common practice and recommended to have a dedicated back-up SOP. The following is stated in the 2004 Draft Guidance: Backup records should be stored at a secure location specified in the SOPs. Storage is typically off-site or in a building separate from the original records. Items to think about while developing SOPs on backup and recovery: Has the entire backup and restoration process been described? This should include backup success verification, backup media, and problem resolution. Is the transport and storage of backup tapes secure? What is the scope of data backup (e.g.: all data, production data, source, test data, software)? What is the backup frequency and scheduling? Once a week, full back-up and daily incremental, differential, or back-up changes to data instantly to another server at another location? That depends on the criticality of the data. What is the backup retention schedule and how is the quality of the data maintained? If there is a need to send the final results to the sponsor, has the data been archived according to the archiving strategy? Is there still a need to keep the back-up tapes? How is the restoration of data managed? This includes: frequency of restoration testing, what can be restored, how long to retain data (for customers) to request restoration? Have you ever tested that restoration works (from old data)? As highlighted in the 2004 Draft Guidance, the FDA is moving to a more documented risk-based approach, stating: Firms that rely on electronic and paper systems should determine the extent to which backup and recovery procedures are needed based on the need to meet predicate rule requirements, a justified and documented risk assessment, and a determination of the potential effect on data quality and record integrity. Needless to say, backup should also include company critical documents that are not covered by the regulatory authorities. Logical and Physical Security Directly related to record integrity is logical and physical security. An SOP should describe the security measures taken. Items that should be considered in an access and security SOP should include: Which secure network shares or applications are identified? Who should have access to which areas (buildings, secure rooms, such as archive, server room, sample storage, laboratory area) and is this controlled? Who are system administrators? Who is allowed to authorize accounts? Details about fire protection. Do your employees know what to do in case of fire? Is correct use made of electrical backup or Uninterrupted Power Supplies (UPS)? That is, if the power goes down, are batteries strong enough to keep the equipment running or do you need to bring the equipment back on-line again? Is it appropriate to have a (diesel) generator to keep your equipment going? 42 Journal of GXP Compliance

8 IVTGXP_july06.qxd 6/28/06 1:09 PM Page 43 Compliance with 21 CFR Part 11 Figure 2 Proposed Part 11 Approach PROPOSED PART 11 APPROACH Determine Predicate Rule Requirements Narrow Scope - Identify Electronic Records that Require Part 11 Compliance Part 11 Records Not Part 11 Records Assess Risk - Evaluate Level of Controls Appropriate to Risk Implement Appropriate Part 11 Controls Furthermore the logical security measures taken should be described as well. Items that should be considered include the following: The process to approve, activate, and deactivate accounts, every user should have a unique ID; is this process documented? A description of the access levels, e.g., defined by role. Can you show for each employee to which network areas and applications they have access and what the level of access is? Unauthorized attempts to access systems should be monitored in a timely manner. How frequently is this done? Systems should be set-up to facilitate log-off after an idle period and enforce change of password after a specified period. Do the applications in use in the laboratory and the workstations facilitate this? Compliance with 21 CFR Part 11 Because the scope of 21 CFR Part 11 has been narrowed by the FDA as stated in the current guidance for industry, 5 the first question to answer should be something like: must my system still comply with Part 11, and if so, which Part 11 controls should be implemented? One way to analyze the need for compliance has been given by FDA officials 8 as visualized in Figure 2. The result of this analysis should be documented. Under a narrow interpretation, FDA considers Part 11 to be applicable to the following records: Records that are required to be maintained under predicate rule requirements and that are maintained in electronic format in place of paper format. Records that are required to be maintained under predicate rules, that are maintained in electronic format in addition to paper format, and that are relied on to perform regulated July 2006 Volume 10, Number 4 43

9 IVTGXP_july06.qxd 6/28/06 1:09 PM Page 44 activities. Records submitted to FDA, under predicate rules (even if such records are not specifically identified in Agency regulations) in electronic format. Many laboratory records are included in submissions and are, therefore, covered by Part 11. It is important to remember that Part 11 is not a regulation about computers. It is about electronic records and signatures. Depending on the applicability of Part 11, appropriate controls should be implemented. The system risk analysis and the implemented Part 11 controls should cover items such as: Are the electronic records identified? Have all the electronic records produced in the laboratory been reviewed? Is a documented process for record management (including storage or archiving, back-up, etc.) in place? Does this process cover the laboratory records as well? Do any applicable records that may be altered have an audit trail? Are the records secure? Is there appropriate password management? Is data transferred, and if so, is it controlled? For example, the way data is transferred to the sponsor. Are Electronic Signatures in use? If so, do they comply with Part 11? Does the signature, for example, link irreversibly to the record it belongs to and does a statement explain what the signature means? Close-out Meeting The audit should typically be closed with a meeting wherein all the key staff of the auditee and the auditors meet and the auditors present the outcome of the audit and motivate findings, if any. Typically, the following will be covered: The audit findings, both positive and negative. It is important that when the auditor leaves the premises of the auditee, the meaning of the finding(s) have been made completely clear. Reporting requirements and documentation logistics are completely understood. Typically, the auditor will send a report or a summary with the outcome of the audit, including the finding(s), so that the auditee can work to resolve them. It is important that the auditee sets realistic deadlines for the completion of the finding(s) and to follow-up on the resolution of those findings. CONCLUSION In this article, a typical audit process and key areas of review are described. However, each specific audit may vary depending on the services the auditee provides and the focus of the auditor. Depending on the size of the auditee s company and scope of the audit, other agenda items may be added such as: The vendor management process (if auditee has outsourced tasks) The IT infrastructure Once the audit has been performed, the findings must be evaluated against the potential risks of problems occurring due to outstanding issue(s). The relevance of the issues should be documented and a report should be sent to the auditee. It is important to follow-up on the report by the group or individual managing the auditee to assure that issues are resolved. If serious issues were discovered, remediation and rectification timeframes should be established and a follow-up audit scheduled to assess progress in these areas. Although a comprehensive story cannot be told here, the issues discussed endeavor to indicate a good starting point and provide guidance to point you in the right directions. ABOUT THE AUTHOR studied Biochemistry at the Nijmegen University in The Netherlands. Since 1994 has been employed by Eli Lilly and Company and has held a variety of positions of increased responsibility since 44 Journal of GXP Compliance

10 IVTGXP_july06.qxd 6/28/06 1:09 PM Page 45 then. As a Lilly Computer System Quality Assurance Auditor he has audited a variety of companies and internal departments regarding computer systems. Currently he is doing a two year Executive Master Course on IT-auditing at the Erasmus University of Rotterdam. REFERENCES 1. Guideline for Good Clinical Practice (GCP) ICH Harmonised Tripartite Guideline (ICH Topic E) 2. U.S. FDA Glossary of Computerized Systems and Software Development Terminology 3. ISO 19011:2002 Guidelines for Quality and/or Environmental Management Systems Auditing 4. U.S. FDA 21 CFR Part 11: Electronic Records; Electronic Signatures (August 1997) 5. U.S. FDA, Guidance for Industry, Part 11, Electronic Records; Electronic Signatures - Scope and Application (August 2003) 6. U.S. FDA, Guidance for Industry, Computerized Systems Used in Clinical Trials (April 1999 and draft released: September 2004) 7. U.S. FDA Public Health Services Act - Title 42 - The Public Health and Welfare, Chapter 6A - Public Health Service 8. Presentation of Joe Famulare, Scott McIntire, J. Murray, U.S. FDA: 21 CFR Part 11 - Scope and Application - Inspection and Enforcement Discretion SUGGESTED READING and REGULATORY REFERENCES U.S. FDA 21 CFR Part 58, Good Laboratory Practice for non-clinical Laboratory Studies (April 2003) U.S. CFR Part 211, sub-part I, Laboratory Controls, April 1996 EU GMP Guide, Annex 11, Computerized Systems, October 2003 U.S. FDA 42 CFR Part 493, Laboratory Requirements (October 2003) Clinical Laboratory Improvement Amendments of 1988 (CLIA) U.S. FDA, Guidance for Industry, Computerized Systems Used in Clinical Trials, April 1999 (draft released: September 2004) U.S. FDA, Guidance for Industry, Part 11, Electronic Records; Electronic Signatures - Scope and Application (August 2003) General Principles of Software Validation; Final Guidance for Industry and FDA Staff (FDA, Center for Devices and Radiological Health, Center for Biologics Evaluation and Research, January 2002) PIC/S Good Practices for Computerized Systems in Regulated GXP Environments (August 2003) (Pharmaceutical Inspection Convention) OECD Principles of Good Laboratory Practice, 1997/98 (Organisation for Economic Co-operation and Development) OECD The Application of the Principles of GLP to Computerised Systems, 1995 GAMP Validation of Laboratory Computerized Systems, April 2005 (Good Automated Manufacturing Practices) BCP CFR CLIA COTS CV DRP EQ EU FDA GAMP GCP GXP ICH IQ ISO IT LIMS OECD SDLC SOP U.S. UPS Article Acronym Listing Business Continuity Plan Code of Federal Regulations Clinical Laboratory Improvement Amendment Commercial-Off-The-Shelf (Software) Curriculum Vitae Disaster Recovery Plan Equipment Qualification European Union Food and Drug Administration Good Automated Manufacturing Practice Good Clinical Practice Good Manufacturing, Clinical, Laboratory, etc., Practice International Conference on Harmonization Installation Qualification International Organization for Standardization Information Technology Laboratory Information Management System Organization for Economic Cooperation and Development Software Development Lifecycle Standard Operating Procedure United States Uninterrupted Power Supply July 2006 Volume 10, Number 4 45

INTRODUCTION. This book offers a systematic, ten-step approach, from the decision to validate to

INTRODUCTION. This book offers a systematic, ten-step approach, from the decision to validate to INTRODUCTION This book offers a systematic, ten-step approach, from the decision to validate to the assessment of the validation outcome, for validating configurable off-the-shelf (COTS) computer software

More information

OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT

OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT PA/PH/OMCL (08) 69 3R Full document title and reference Document type VALIDATION OF COMPUTERISED SYSTEMS Legislative basis - CORE DOCUMENT

More information

Guidance for Industry Computerized Systems Used in Clinical Investigations

Guidance for Industry Computerized Systems Used in Clinical Investigations Guidance for Industry Computerized Systems Used in Clinical Investigations U.S. Department of Health and Human Services Food and Drug Administration (FDA) Office of the Commissioner (OC) May 2007 Guidance

More information

Eclipsys Sunrise Clinical Manager Enterprise Electronic Medical Record (SCM) and Title 21 Code of Federal Regulations Part 11 (21CFR11)

Eclipsys Sunrise Clinical Manager Enterprise Electronic Medical Record (SCM) and Title 21 Code of Federal Regulations Part 11 (21CFR11) Eclipsys Sunrise Clinical Manager Enterprise Electronic Medical Record (SCM) and Title 21 Code of Federal Regulations Part 11 (21CFR11) The title 21 code of federal regulations part 11 deals with an institutions

More information

This interpretation of the revised Annex

This interpretation of the revised Annex Reprinted from PHARMACEUTICAL ENGINEERING The Official Magazine of ISPE July/August 2011, Vol. 31 No. 4 www.ispe.org Copyright ISPE 2011 The ISPE GAMP Community of Practice (COP) provides its interpretation

More information

Guidance for Industry Part 11, Electronic Records; Electronic Signatures Scope and Application

Guidance for Industry Part 11, Electronic Records; Electronic Signatures Scope and Application Guidance for Industry Part 11, Electronic Records; Electronic Signatures Scope and Application U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research

More information

Clinical database/ecrf validation: effective processes and procedures

Clinical database/ecrf validation: effective processes and procedures TITOLO SLIDE Testo Slide Testo Slide Testo Slide Clinical database/ecrf validation: effective processes and procedures IV BIAS ANNUAL CONGRESS Padova September, 26 th 2012 PQE WORKSHOP: What's new in Computerized

More information

Qualification Guideline

Qualification Guideline Qualification Guideline June 2013 Disclaimer: This document is meant as a reference to Life Science companies in regards to the Microsoft O365 platform. Montrium does not warrant that the use of the recommendations

More information

Guidance for Industry COMPUTERIZED SYSTEMS USED IN CLINICAL TRIALS

Guidance for Industry COMPUTERIZED SYSTEMS USED IN CLINICAL TRIALS Guidance for Industry COMPUTERIZED SYSTEMS USED IN CLINICAL TRIALS U.S. Department of Health and Human Services Food and Drug Administration Center for Biologic Evaluation and Research (CBER) Center for

More information

Computerised Systems. Seeing the Wood from the Trees

Computerised Systems. Seeing the Wood from the Trees Computerised Systems Seeing the Wood from the Trees Scope WHAT IS A COMPUTERISED SYSTEM? WHY DO WE NEED VALIDATED SYSTEMS? WHAT NEEDS VALIDATING? HOW DO WE PERFORM CSV? WHO DOES WHAT? IT S VALIDATED -

More information

OECD DRAFT ADVISORY DOCUMENT 16 1 THE APPLICATION OF GLP PRINCIPLES TO COMPUTERISED SYSTEMS FOREWARD

OECD DRAFT ADVISORY DOCUMENT 16 1 THE APPLICATION OF GLP PRINCIPLES TO COMPUTERISED SYSTEMS FOREWARD OECD DRAFT ADVISORY DOCUMENT 16 1 THE APPLICATION OF GLP PRINCIPLES TO COMPUTERISED SYSTEMS FOREWARD 1. The following draft Advisory Document will replace the 1995 OECD GLP Consensus Document number 10

More information

Computer System Validation - It s More Than Just Testing

Computer System Validation - It s More Than Just Testing Computer System Validation - It s More Than Just Testing Introduction Computer System Validation is the technical discipline that Life Science companies use to ensure that each Information Technology application

More information

Back to index of articles. Qualification of Computer Networks and Infrastructure

Back to index of articles. Qualification of Computer Networks and Infrastructure Back to index of articles Qualification of Computer Networks and Infrastructure R.D.McDowall McDowall Consulting Validation of computerised systems generally focuses on the providing documented evidence

More information

Testing Automated Manufacturing Processes

Testing Automated Manufacturing Processes Testing Automated Manufacturing Processes (PLC based architecture) 1 ❶ Introduction. ❷ Regulations. ❸ CSV Automated Manufacturing Systems. ❹ PLCs Validation Methodology / Approach. ❺ Testing. ❻ Controls

More information

REGULATIONS COMPLIANCE ASSESSMENT

REGULATIONS COMPLIANCE ASSESSMENT ALIX is free software: you can redistribute it and/or modify it under the terms of the GNU General Public License as published by the Free Software Foundation. REGULATIONS COMPLIANCE ASSESSMENT BUSINESS

More information

GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group dpifat@bcg-usa.com

GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group dpifat@bcg-usa.com GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group dpifat@bcg-usa.com Common Misconception Good Laboratory Practices 1) A quality system concerned with the organizational process

More information

Adoption by GCP Inspectors Working Group for consultation 14 June 2011. End of consultation (deadline for comments) 15 February 2012

Adoption by GCP Inspectors Working Group for consultation 14 June 2011. End of consultation (deadline for comments) 15 February 2012 10 December 2013 EMA/INS/GCP/600788/2011 Compliance and Inspection Reflection paper on the use of interactive response technologies (interactive voice/web response systems) in clinical trials, with particular

More information

Considerations When Validating Your Analyst Software Per GAMP 5

Considerations When Validating Your Analyst Software Per GAMP 5 WHITE PAPER Analyst Software Validation Service Considerations When Validating Your Analyst Software Per GAMP 5 Blair C. James, Stacy D. Nelson Introduction The purpose of this white paper is to assist

More information

What is the correct title of this publication? What is the current status of understanding and implementation?

What is the correct title of this publication? What is the current status of understanding and implementation? GMP Rules and Guidelines in 2013 for Computer System Validation / Computerises Systems / Electronic Records and Signatures/ IT Infrastructure and Application Compliance: What is the correct title of this

More information

COTS Validation Post FDA & Other Regulations

COTS Validation Post FDA & Other Regulations COTS Validation Post FDA & Other Regulations TABLE OF CONTENTS 1. Abstract 3 2. What is COTS 3 3. Why should COTS require Validation? 3 4. Risk Based Approach 4 5. Validation Approach 6 6. Applicable Regulations

More information

The Concept of Quality in Clinical Research. Dorota Śwituła Senior Clinical Quality Assurance Advisor

The Concept of Quality in Clinical Research. Dorota Śwituła Senior Clinical Quality Assurance Advisor The Concept of Quality in Clinical Research Dorota Śwituła Senior Clinical Quality Assurance Advisor 1 Agenda What is quality? How we define quality in clinical research? The standard components of a Quality

More information

GAMP 4 to GAMP 5 Summary

GAMP 4 to GAMP 5 Summary GAMP 4 to GAMP 5 Summary Introduction This document provides summary information on the GAMP 5 Guide and provides a mapping to the previous version, GAMP 4. It specifically provides: 1. Summary of Need

More information

The use of computer systems

The use of computer systems Technology Update Computer Systems Validation, Part 1 Software Purchase and GCP Compliance Teri Stokes Teri Stokes, PhD, is senior consultant and director of GXP International, 131 Sudbury Road, Concord,

More information

Auditing as a Component of a Pharmaceutical Quality System

Auditing as a Component of a Pharmaceutical Quality System Auditing as a Component of a Pharmaceutical Quality System Tim Fields Conducting internal audits (or self inspections) and external audits of suppliers and outsourcing operations are key elements of a

More information

TIBCO Spotfire and S+ Product Family

TIBCO Spotfire and S+ Product Family TIBCO Spotfire and S+ Product Family Compliance with 21 CFR Part 11, GxP and Related Software Validation Issues The Code of Federal Regulations Title 21 Part 11 is a significant regulatory requirement

More information

Business Continuity Planning and Disaster Recovery Planning

Business Continuity Planning and Disaster Recovery Planning 4 Business Continuity Planning and Disaster Recovery Planning Basic Concepts 1. Business Continuity Management: Business Continuity means maintaining the uninterrupted availability of all key business

More information

Supplement to the Guidance for Electronic Data Capture in Clinical Trials

Supplement to the Guidance for Electronic Data Capture in Clinical Trials Supplement to the Guidance for Electronic Data Capture in Clinical Trials January 10, 2012 Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association Note: The original language of this

More information

Compliance Response Edition 07/2009. SIMATIC WinCC V7.0 Compliance Response Electronic Records / Electronic Signatures. simatic wincc DOKUMENTATION

Compliance Response Edition 07/2009. SIMATIC WinCC V7.0 Compliance Response Electronic Records / Electronic Signatures. simatic wincc DOKUMENTATION Compliance Response Edition 07/2009 SIMATIC WinCC V7.0 Compliance Response Electronic Records / Electronic Signatures simatic wincc DOKUMENTATION Compliance Response Electronic Records / Electronic Signatures

More information

Considerations for validating SDS Software v2.x Enterprise Edition for the 7900HT Fast Real-Time PCR System per the GAMP 5 guide

Considerations for validating SDS Software v2.x Enterprise Edition for the 7900HT Fast Real-Time PCR System per the GAMP 5 guide WHITE PAPER SDS Software v2.x Enterprise Edition Considerations for validating SDS Software v2.x Enterprise Edition for the 7900HT Fast Real-Time PCR System per the GAMP 5 guide This white paper describes

More information

Sponsor Site Questionnaire FAQs Regarding Maestro Care

Sponsor Site Questionnaire FAQs Regarding Maestro Care Sponsor Site Questionnaire FAQs Regarding Maestro Care Data Security and Validation 1. Are the electronic source documents or computer systems specific to the site and/or developed by the site? a. Developed

More information

Good Clinical Practice 101: An Introduction

Good Clinical Practice 101: An Introduction Good Clinical Practice 101: An Introduction Presented by: Lester Jao Lacorte, MD Medical Officer Commissioner s Fellow Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological

More information

Compliance Response SIMATIC SIMATIC PCS 7 V8.1. Electronic Records / Electronic Signatures (ERES) Edition 03/2015. Answers for industry.

Compliance Response SIMATIC SIMATIC PCS 7 V8.1. Electronic Records / Electronic Signatures (ERES) Edition 03/2015. Answers for industry. SIMATIC SIMATIC PCS 7 V8.1 Electronic Records / Electronic Signatures (ERES) Compliance Response Edition 03/2015 Answers for industry. Compliance Response Electronic Records / Electronic Signatures (ERES)

More information

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public Health and Risk Assessment Pharmaceuticals Brussels, SANCO/C8/AM/sl/ares(2010)1064599 EudraLex The Rules Governing Medicinal Products

More information

Disaster Recovery and Business Continuity

Disaster Recovery and Business Continuity Disaster Recovery and Business Continuity Barbara Nollau Rupert King/Getty Images Computer Systems Quality and Compliance discusses practical aspects of computer systems and provides useful information

More information

European Forum for Good Clinical Practice Audit Working Party

European Forum for Good Clinical Practice Audit Working Party European Forum for Good Clinical Practice Audit Working Party REVISION OF THE ENGAGE 1 AUDITING GUIDELINE. AN OPTIONAL GUIDELINE FOR GCP COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS AUDITING This document

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Electronic Source Data in Clinical Investigations U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for

More information

From paper to electronic data

From paper to electronic data From paper to electronic data Bioindustrypark, October 10, 2013 Dr Alessandra Grande Ivrea GxP Test Facility QA Manager, Head Global BMT QA Research & Development Quality Assurance MerckSerono RBM Outline

More information

Overview. Disasters are happening more frequently and Recovery is taking on a different perspective.

Overview. Disasters are happening more frequently and Recovery is taking on a different perspective. Overview Disasters are happening more frequently and Recovery is taking on a different perspective. Defining a Disaster/Disaster Recovery Basic requirements in preparing for a disaster The role of Quality

More information

Risk-Based Validation of Computer Systems Used In FDA-Regulated Activities

Risk-Based Validation of Computer Systems Used In FDA-Regulated Activities September 2, 2003 Risk-Based Validation of Computer Systems Used In FDA-Regulated Activities Purpose This document provides a summary of the requirements relating to use of computer-based systems in activities

More information

GCP INSPECTORS WORKING GROUP <DRAFT> REFLECTION PAPER ON EXPECTATIONS FOR ELECTRONIC SOURCE DOCUMENTS USED IN CLINICAL TRIALS

GCP INSPECTORS WORKING GROUP <DRAFT> REFLECTION PAPER ON EXPECTATIONS FOR ELECTRONIC SOURCE DOCUMENTS USED IN CLINICAL TRIALS European Medicines Agency London, 17 October 2007 Doc. Ref. EMEA/505620/2007 GCP INSPECTORS WORKING GROUP REFLECTION PAPER ON EXPECTATIONS FOR ELECTRONIC SOURCE DOCUMENTS USED IN CLINICAL TRIALS

More information

LabChip GX/GXII with LabChip GxP Software

LabChip GX/GXII with LabChip GxP Software Regulatory Compliance LabChip GX/GXII with LabChip GxP Software Supporting Regulatory Compliance Caliper LabChip GX/GXII suite of instruments provides automated electrophoresis to analyze quality, size,

More information

OECD SERIES ON PRINCIPLES OF GOOD LABORATORY PRACTICE AND COMPLIANCE MONITORING NUMBER 10 GLP CONSENSUS DOCUMENT

OECD SERIES ON PRINCIPLES OF GOOD LABORATORY PRACTICE AND COMPLIANCE MONITORING NUMBER 10 GLP CONSENSUS DOCUMENT GENERAL DISTRIBUTION OCDE/GD(95)115 OECD SERIES ON PRINCIPLES OF GOOD LABORATORY PRACTICE AND COMPLIANCE MONITORING NUMBER 10 GLP CONSENSUS DOCUMENT THE APPLICATION OF THE PRINCIPLES OF GLP TO COMPUTERISED

More information

Guidance for Industry. 21 CFR Part 11; Electronic. Records; Electronic Signatures. Time Stamps

Guidance for Industry. 21 CFR Part 11; Electronic. Records; Electronic Signatures. Time Stamps Guidance for Industry 21 CFR Part 11; Electronic Records; Electronic Signatures Time Stamps Draft Guidance This guidance document is being distributed for comment purposes only. Comments and suggestions

More information

CLINICAL DATA MONITORING PLAN (CDMoP) PROTOCOL # [0000] [TITLE]

CLINICAL DATA MONITORING PLAN (CDMoP) PROTOCOL # [0000] [TITLE] CLINICAL DATA MONITORING PLAN (CDMoP) PROTOCOL # [0000] [TITLE] CONTRACT RESEARCH ORGANIZATION SPONSOR [NAME] [ADDRESS] 1 TABLE OF CONTENTS 1. Purpose 3 2. References 3 3. Study Roles and Responsibilities

More information

Full Compliance Contents

Full Compliance Contents Full Compliance for and EU Annex 11 With the regulation support of Contents 1. Introduction 2 2. The regulations 2 3. FDA 3 Subpart B Electronic records 3 Subpart C Electronic Signatures 9 4. EU GMP Annex

More information

Title:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions

Title:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions WELCOME Title:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions Contents: Introduction GMP Audit GMP Audit plan GMP Auditing

More information

Validating Cloud. June 2012 Merry Danley

Validating Cloud. June 2012 Merry Danley Validating Cloud June 2012 Merry Danley Agenda Validation of Cloud Introduction Environments Definitions Manage Risk by Designation of Systems Why Go Cloud Success Dependencies Validation Personal Experience

More information

Validated SaaS LMS SuccessFactors Viability

Validated SaaS LMS SuccessFactors Viability Validated SaaS LMS SuccessFactors Viability Executive Summary SuccessFactors has a long history of working with validated organizations and has brought this expertise to their validated SaaS LMS package.

More information

Declaration of Conformity 21 CFR Part 11 SIMATIC WinCC flexible 2007

Declaration of Conformity 21 CFR Part 11 SIMATIC WinCC flexible 2007 Declaration of Conformity 21 CFR Part 11 SIMATIC WinCC flexible 2007 SIEMENS AG Industry Sector Industry Automation D-76181 Karlsruhe, Federal Republic of Germany E-mail: pharma.aud@siemens.com Fax: +49

More information

EVALUATION REPORT. Weaknesses Identified During the FY 2014 Federal Information Security Management Act Review. March 13, 2015 REPORT NUMBER 15-07

EVALUATION REPORT. Weaknesses Identified During the FY 2014 Federal Information Security Management Act Review. March 13, 2015 REPORT NUMBER 15-07 EVALUATION REPORT Weaknesses Identified During the FY 2014 Federal Information Security Management Act Review March 13, 2015 REPORT NUMBER 15-07 EXECUTIVE SUMMARY Weaknesses Identified During the FY 2014

More information

PKI Adoption Case Study (for the OASIS PKIA TC) ClinPhone Complies with FDA Regulations Using PKIbased Digital Signatures

PKI Adoption Case Study (for the OASIS PKIA TC) ClinPhone Complies with FDA Regulations Using PKIbased Digital Signatures PKI Adoption Case Study (for the OASIS PKIA TC) ClinPhone Complies with FDA Regulations Using PKIbased Digital Signatures PKI Project Title Digital Signatures for ClinPhone Organisation concerned ClinPhone

More information

FDA Title 21 CFR Part 11:Electronic Records; Electronic Signatures; Final Rule (1997)

FDA Title 21 CFR Part 11:Electronic Records; Electronic Signatures; Final Rule (1997) www.qadata.co.za Introduction FDA Title 21 CFR Part 11:Electronic Records; Electronic Signatures; Final Rule (1997) INITIAL REGULATION RELEASED High profile audit findings Industry complaints to wasting

More information

Guidance for electronic trial data capturing of clinical trials

Guidance for electronic trial data capturing of clinical trials Guidance for electronic trial data capturing of clinical trials 1 st November, 2007 Japan Pharmaceutical Manufacturing Association pg. 1 Table of Contents 1. Background... 3 2. Purpose... 3 3. Scope...

More information

Guidance for Industry. Q10 Pharmaceutical Quality System

Guidance for Industry. Q10 Pharmaceutical Quality System Guidance for Industry Q10 Pharmaceutical Quality System U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation

More information

21 CFR Part 11 Checklist

21 CFR Part 11 Checklist 21 CFR Part 11 Checklist GUIDE NOTOCORD - 113 Chemin de Ronde - 78290 Croissy-sur-Seine www.notocord.com my.notocord.com support@notocord.com +33 (0)1 34 80 00 00 1. Preliminary information 1.1. Purpose

More information

GLP Records Storage and Retrieval

GLP Records Storage and Retrieval GLP Records Storage and Retrieval Cindy Green BBS UNITED, ALEX HAYDEN/GETTY IMAGES GLP Topics addresses topics associated with good laboratory practice requirements. We intend this column to be a useful

More information

Risk-Based Approach to 21 CFR Part 11

Risk-Based Approach to 21 CFR Part 11 3109 W. Dr. Martin Luther King, Jr. Blvd., Suite 250 Tampa, FL 33607 USA Tel: 813/960-2105 Fax: 813/264-2816 www.ispe.org Risk-Based Approach to 21 CFR Part 11 The 21 CFR Part 11 regulation is a comprehensive

More information

PHARMACEUTICAL QUALITY SYSTEM Q10

PHARMACEUTICAL QUALITY SYSTEM Q10 INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE PHARMACEUTICAL QUALITY SYSTEM Q10 Current Step

More information

Data Center Assistance Group, Inc. DCAG Contact: Tom Bronack Phone: (718) 591-5553 Email: bronackt@dcag.com Fax: (718) 380-7322

Data Center Assistance Group, Inc. DCAG Contact: Tom Bronack Phone: (718) 591-5553 Email: bronackt@dcag.com Fax: (718) 380-7322 Business Continuity and Disaster Recovery Job Descriptions Table of Contents Business Continuity Services Organization Chart... 2 Director Business Continuity Services Group... 3 Manager of Business Recovery

More information

Overview of how to test a. Business Continuity Plan

Overview of how to test a. Business Continuity Plan Overview of how to test a Business Continuity Plan Prepared by: Thomas Bronack Phone: (718) 591-5553 Email: bronackt@dcag.com BRP/DRP Test Plan Creation and Exercise Page: 1 Table of Contents BCP/DRP Test

More information

Implementing Title 21 CFR Part 11 (Electronic Records ; Electronic Signatures) in Manufacturing Presented by: Steve Malyszko, P.E.

Implementing Title 21 CFR Part 11 (Electronic Records ; Electronic Signatures) in Manufacturing Presented by: Steve Malyszko, P.E. Implementing Title 21 CFR Part 11 (Electronic Records ; Electronic Signatures) in Manufacturing Presented by: Steve Malyszko, P.E. President & CEO Agenda Introduction Who is Malisko Engineering? Title

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Electronic Source Data in Clinical Investigations DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft

More information

IT General Controls Domain COBIT Domain Control Objective Control Activity Test Plan Test of Controls Results

IT General Controls Domain COBIT Domain Control Objective Control Activity Test Plan Test of Controls Results Acquire or develop application systems software Controls provide reasonable assurance that application and system software is acquired or developed that effectively supports financial reporting requirements.

More information

ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS

ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS STANDARD OPERATING PROCEDURE NO SOP 09 DATE RATIFIED 4/7/13 NEXT REVIEW DATE 4/7/14 POLICY STATEMENT/KEY OBJECTIVES:

More information

Disaster Recovery & Business Continuity Related, but NOT the Same! Teri Stokes, Ph.D., Director GXP International

Disaster Recovery & Business Continuity Related, but NOT the Same! Teri Stokes, Ph.D., Director GXP International Disaster Recovery & Business Continuity Related, but NOT the Same! Teri Stokes, Ph.D., Director GXP International BCP Definitions Business Continuity Plan: An ongoing process supported by senior management

More information

Welcome Computer System Validation Training Delivered to FDA. ISPE Boston Area Chapter February 20, 2014

Welcome Computer System Validation Training Delivered to FDA. ISPE Boston Area Chapter February 20, 2014 Welcome Computer System Validation Training Delivered to FDA ISPE Boston Area Chapter February 20, 2014 1 Background Training Conducted on April 24, 2012 Food & Drug Administration Division of Manufacturing

More information

QUALITY CONTROL AND QUALITY ASSURANCE IN CLINICAL RESEARCH

QUALITY CONTROL AND QUALITY ASSURANCE IN CLINICAL RESEARCH QUALITY CONTROL AND QUALITY ASSURANCE IN CLINICAL RESEARCH Martin Valania, Executive Director, Corporate QA and Compliance Introduction Pharmaceutical companies recognize the benefits of carefully managing

More information

Data Management and Good Clinical Practice Patrick Murphy, Research Informatics, Family Health International

Data Management and Good Clinical Practice Patrick Murphy, Research Informatics, Family Health International Data Management and Good Clinical Practice Patrick Murphy,, Family Health International 1 What is GCP? Good Clinical Practice is an international ethical and scientific quality standard for designing,

More information

Manual 074 Electronic Records and Electronic Signatures 1. Purpose

Manual 074 Electronic Records and Electronic Signatures 1. Purpose 1. Purpose The purpose of this document is to provide an interpretation of FDA 21 CFR Part 11, Electronic Records; Electronic Signatures (ER/ES) and to provide guidance for acceptable practices in the

More information

CONTENTS. List of Tables List of Figures

CONTENTS. List of Tables List of Figures Prelims 13/3/06 9:11 pm Page iii CONTENTS List of Tables List of Figures ix xi 1 Introduction 1 1.1 The Need for Guidance on ERP System Validation 1 1.2 The Need to Validate ERP Systems 3 1.3 The ERP Implementation

More information

Good Clinical Laboratory Practice (GCLP) An international quality system for laboratories which undertake the analysis of samples from clinical trials

Good Clinical Laboratory Practice (GCLP) An international quality system for laboratories which undertake the analysis of samples from clinical trials Good Clinical Laboratory Practice (GCLP) An international quality system for laboratories which undertake the analysis of samples from clinical trials Vanessa Grant and Tim Stiles VERSION 2 Published by

More information

The Global Guideline for GCP Audit

The Global Guideline for GCP Audit The Global Guideline for GCP Audit Author: JSQA: Hiroyasu Yamashita, e-mail: hiroyasu-yamashita@ds-pharma.co.jp Reviewed and Acknowledged by: BARQA: Patricia Fitzgerald, e-mail: Patricia.fitzgerald@adamas.co.uk

More information

Reflection paper on the Use of Interactive Response Technologies (Interactive Voice/Web Response Systems) in Clinical Trials

Reflection paper on the Use of Interactive Response Technologies (Interactive Voice/Web Response Systems) in Clinical Trials 1 2 3 5 August 2011 EMA/INS/GCP/600788/2011 Compliance and Inspection 4 5 6 7 Reflection paper on the Use of Interactive Response Technologies (Interactive Voice/Web Response Systems) in Clinical Trials

More information

Off-the-Shelf Software: A Broader Picture By Bryan Chojnowski, Reglera Director of Quality

Off-the-Shelf Software: A Broader Picture By Bryan Chojnowski, Reglera Director of Quality Off-the-Shelf Software: A Broader Picture By Bryan Chojnowski, Reglera Director of Quality In the past decade, there has been a sea change in the business software domain. Many companies are no longer

More information

Disaster Recovery and Business Continuity Plan

Disaster Recovery and Business Continuity Plan Disaster Recovery and Business Continuity Plan Table of Contents 1. Introduction... 3 2. Objectives... 3 3. Risks... 3 4. Steps of Disaster Recovery Plan formulation... 3 5. Audit Procedure.... 5 Appendix

More information

ACDM GUIDELINES TO FACILITATE PRODUCTION OF A DATA HANDLING PROTOCOL

ACDM GUIDELINES TO FACILITATE PRODUCTION OF A DATA HANDLING PROTOCOL ACDM GUIDELINES TO FACILITATE PRODUCTION OF A DATA HANDLING PROTOCOL BACKGROUND The need was identified by the Electronic Data Transfer Special Interest Group (SIG) for each company or organisation to

More information

MHRA GMP Data Integrity Definitions and Guidance for Industry January 2015

MHRA GMP Data Integrity Definitions and Guidance for Industry January 2015 MHRA GMP Data Integrity Definitions and Guidance for Industry Introduction: Data integrity is fundamental in a pharmaceutical quality system which ensures that medicines are of the required quality. This

More information

Electronic records and electronic signatures in the regulated environment of the pharmaceutical and medical device industries

Electronic records and electronic signatures in the regulated environment of the pharmaceutical and medical device industries White Paper No 01 I December 2010 Implementation of 21 CFR Part 11 in the epmotion Software Electronic records and electronic signatures in the regulated environment of the pharmaceutical and medical device

More information

Document Number: SOP/RAD/SEHSCT/007 Page 1 of 17 Version 2.0

Document Number: SOP/RAD/SEHSCT/007 Page 1 of 17 Version 2.0 Standard Operating Procedures (SOPs) Research and Development Office Title of SOP: Computerised Systems for Clinical Trials SOP Number: 7 Version Number: 2.0 Supercedes: 1.0 Effective date: August 2013

More information

Computer System Configuration Management and Change Control

Computer System Configuration Management and Change Control Computer System Configuration Management and Change Control What Your IT Department Is Really Doing Justin J. Fisher, Pfizer IT Quality and Compliance Manager Agenda 1. Background 2. Audience Demographics

More information

QUALITY SYSTEM REQUIREMENTS FOR PHARMACEUTICAL INSPECTORATES

QUALITY SYSTEM REQUIREMENTS FOR PHARMACEUTICAL INSPECTORATES PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 002-3 25 September 2007 RECOMMENDATION ON QUALITY SYSTEM REQUIREMENTS FOR PHARMACEUTICAL INSPECTORATES PIC/S September

More information

Training Course Computerized System Validation in the Pharmaceutical Industry Istanbul, 16-17 January 2003. Change Control

Training Course Computerized System Validation in the Pharmaceutical Industry Istanbul, 16-17 January 2003. Change Control Training Course Computerized System Validation in the Pharmaceutical Industry Istanbul, 16-17 January 2003 Change Control Wolfgang Schumacher Roche Pharmaceuticals, Basel Agenda Change Control Definitions

More information

International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation

International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation Ludwig Huber, Ph.D. ludwig_huber@labcompliance.com Overview GMP requirements for Quality Control laboratories

More information

Clinical Training Management

Clinical Training Management Clinical Training Management Learning and Compliance for Clinical Research Helping to Fuel the Growth of CROs and Service Providers According to clinical researcher CenterWatch, the FDA and global regulatory

More information

MHRA GMP Data Integrity Definitions and Guidance for Industry March 2015

MHRA GMP Data Integrity Definitions and Guidance for Industry March 2015 MHRA GMP Data Integrity Definitions and Guidance for Industry Introduction: Data integrity is fundamental in a pharmaceutical quality system which ensures that medicines are of the required quality. This

More information

ICH guideline Q10 on pharmaceutical quality system

ICH guideline Q10 on pharmaceutical quality system September 2015 EMA/CHMP/ICH/214732/2007 Committee for Human Medicinal Products Step 5 Transmission to CHMP May 2007 Transmission to interested parties May 2007 Deadline for comments November 2007 Final

More information

Sharon Strause 9/10/2010. 15 years with the

Sharon Strause 9/10/2010. 15 years with the Manage Software Development, Testing, and Validation Presented by Sharon Strause, Senior Consultant EduQuest, Inc. IVT s Computer and Software Validation EU Conference The Hilton Dublin Dublin, Ireland

More information

Computer System Configuration Management and Change Control

Computer System Configuration Management and Change Control Computer System Configuration Management and Change Control Using Risk-Based Decision Making to Plan and Implement IT Change Justin J. Fisher Senior Manager, BT Quality and Compliance Pfizer Agenda 1.

More information

GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE

GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE ICH E6 GCP: Consolidated Guideline: Investigator 1/7 Institutional Review Board Services ICH HARMONIZED TRIPARTITE GUIDELINE E6: GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE 4. INVESTIGATOR 4.1 Investigator's

More information

Validation Consultant

Validation Consultant Personal Data Name Title Validation Consultant Contact jsb-validierung Zwischen den Bächen 9 D 79618 Rheinfelden Tel: +49 7623 79 49 82 Mobile: +49 172 737 84 86 E-Mail: Internet: jsb-val@online.de http://www.jsb-validierung.de

More information

unless the manufacturer upgrades the firmware, whereas the effort is repeated.

unless the manufacturer upgrades the firmware, whereas the effort is repeated. Software Validation in Accredited Laboratories A Practical Guide Gregory D. Gogates Fasor Inc., 3101 Skippack Pike, Lansdale, Pennsylvania 19446-5864 USA g.gogates@ieee.org www.fasor.com Abstract Software

More information

OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT

OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT PA/PH/OMCL (08) 88 R VALIDATION OF COMPUTERISED SYSTEMS ANNEX 2: VALIDATION OF DATABASES (DB), LABORATORY INFORMATION MANAGEMENT SYSTEMS

More information

FINAL May 2005. Guideline on Security Systems for Safeguarding Customer Information

FINAL May 2005. Guideline on Security Systems for Safeguarding Customer Information FINAL May 2005 Guideline on Security Systems for Safeguarding Customer Information Table of Contents 1 Introduction 1 1.1 Purpose of Guideline 1 2 Definitions 2 3 Internal Controls and Procedures 2 3.1

More information

CENTRAL BANK OF KENYA (CBK) PRUDENTIAL GUIDELINE ON BUSINESS CONTINUITY MANAGEMENT (BCM) FOR INSTITUTIONS LICENSED UNDER THE BANKING ACT

CENTRAL BANK OF KENYA (CBK) PRUDENTIAL GUIDELINE ON BUSINESS CONTINUITY MANAGEMENT (BCM) FOR INSTITUTIONS LICENSED UNDER THE BANKING ACT CENTRAL BANK OF KENYA (CBK) PRUDENTIAL GUIDELINE ON BUSINESS CONTINUITY MANAGEMENT (BCM) FOR INSTITUTIONS LICENSED UNDER THE BANKING ACT JANUARY 2008 GUIDELINE ON BUSINESS CONTINUITY GUIDELINE CBK/PG/14

More information

QUESTIONS FOR YOUR SOFTWARE VENDOR: TO ASK BEFORE YOUR AUDIT

QUESTIONS FOR YOUR SOFTWARE VENDOR: TO ASK BEFORE YOUR AUDIT QUESTIONS FOR YOUR SOFTWARE VENDOR: TO ASK BEFORE YOUR AUDIT Heather Longden Senior Marketing Manager Waters Corporation Boston Chapter Educational Meeting June 2016 About Waters Lab Informatics Separations

More information

LIBRARY GUIDE: Clinical Medical Device

LIBRARY GUIDE: Clinical Medical Device LIBRARY GUIDE: Clinical Medical Device Table of Contents Overview... 3 Clinical Curriculum Core Program Course Descriptions: A Tour of Health Canada (PHDV89)...5 A Tour of Health Europe (PHDV90)...5 A

More information

Polish Financial Supervision Authority. Guidelines

Polish Financial Supervision Authority. Guidelines Polish Financial Supervision Authority Guidelines on the Management of Information Technology and ICT Environment Security for Insurance and Reinsurance Undertakings Warsaw, 16 December 2014 Table of Contents

More information

Computer System Validation for Clinical Trials:

Computer System Validation for Clinical Trials: Computer System Validation for Clinical Trials: Framework Standard Operating Procedure (F-SOP) Author: Tim Cross Version History: 0.1di DRAFT 24-April-2013 0.2 DRAFT 12-June-2013 Current Version: 1.0 17-June-2013

More information

074-8432-552 Page 1 of 7 Effective Date: 12/18/03 Software Supplier Process Requirements

074-8432-552 Page 1 of 7 Effective Date: 12/18/03 Software Supplier Process Requirements Page 1 of 7 Software Supplier Process Requirements 1.0 QUALITY SYSTEM FRAMEWORK 1.1 QUALITY POLICY The Seller shall document and implement a quality program in the form of Quality manual or detailed Quality

More information

Development, Acquisition, Implementation, and Maintenance of Application Systems

Development, Acquisition, Implementation, and Maintenance of Application Systems Development, Acquisition, Implementation, and Maintenance of Application Systems Part of a series of notes to help Centers review their own Center internal management processes from the point of view of

More information